Uterus transplantation (UTx) offers women with absolute uterine factor infertility the option to gestate and birth their own biologically related child. The first birth following living donation UTx happened in 2014. The first birth following deceased donation happened in December 2017, with further successes since. Interest in deceased donation UTx is increasing. The authors established a database to track UTx clinical trials and outcomes. Utilising this database and existing literature, this article reviews the first reported cases of deceased donation UTx and outcomes, and drawing upon comparisons with living donor UTx, comments upon the future for this area of reproductive transplantation research. This is the first article to bring together the literature on deceased donation UTx procedures and outcomes.

BACKGROUND: Intraventricular haemorrhage (IVH) is a common problem in preterm infants, being a major cause of morbidity and mortality. Despite many randomised controlled trials comparing interventions to prevent IVH, the best prevention remains unclear. This study aims to review all the interventions which intended to reduce the incidence of IVH and compare them in a network meta-analysis. METHODS: A search on MEDLINE, EMBASE, Emcare, and CENTRAL was performed. Randomised controlled trials which evaluated neonatal interventions with a primary aim to reduce incidence of IVH in preterm infants were eligible. A surface under a cumulative ranking curve (SUCRA) was produced to indicate the intervention’s likelihood of being the most effective for preventing IVH. RESULTS: 40 studies were eligible, enrolling over 6760 infants. Twelve intervention groups were found, including delayed cord clamping, erythropoietin, ethamsylate, fresh frozen plasma, heparin, ibuprofen, indomethacin, magnesium, nursing interventions, sedation, tranexamic acid, and vitamin E. Vitamin E and indomethacin had the highest probability of being the best interventions to prevent IVH in premature infants, but interpretation of these results is difficult due to study limitations. CONCLUSION: Despite the impact of IVH, we were unable to identify a clearly beneficial treatment to reduce its incidence. Interpretation of the network meta-analysis was limited due to differences within studied populations, wide range of therapies trialled, and underlying advances in neonatal care between units, and over time. Although vitamin E and indomethacin appear to be promising candidates, contemporaneous trials of these, or novel agents, enrolling the most at-risk infants is needed urgently.

Introduction Uterine transplantation (UTx) allows women with abnormal uterine factor infertility (AUFI) to have their own biological children. UTx use both living and deceased donations (LD and DD), and once transplanted, embryos fertilised through IVF are implanted. The aims of this review are to summarise the history of UTx and discuss the ethical issues surrounding immunosuppression and living donations for a ‘life enhancing’ transplant. Method Data on UTx, clinical trials and resulting births was found by conducting a literature search on PubMed and other medical databases. Additionally, newspaper articles, institutional press releases and conference proceedings were used as some of the data is yet to be published. Results 72 UTx have been performed which have resulted in 29 live births. The first LD UTx was performed in 2000 but was removed due to graft thrombosis. The first live births from LD and DD UTx were achieved in 2014 and 2017 respectively. Conclusions Live births provide proofs of concept of UTx. Graft rejection, vessel thrombosis and infection are amongst reasons for graft failure. Development of an international registry for UTx is important to monitor the progress of all transplants in the long term to determine its medical and ethical feasibility as a treatment for AUFI.

impact of scientific-based geriatric, psychological and functional assessments based on mental, emotional, disease-related and patient-reported outcome measures (PROM), as well as to assess clinicopathological and disease-related variables. Based on this evidence, a predictive score will be developed. In a second stage of the study, we also plan to evaluate its predictive power to identify those fragile patients who will interrupt or discontinue recurrent chemotherapy within the first 12 weeks of therapy. Results / Conclusion / 2022-RA-1084-ESGO ONCOLOGICAL OUTCOMES IN PATIENTS